Kantify
Kantify is a company leveraging Artificial Intelligence (AI) to accelerate drug discovery and develop breakthrough therapies. Their AI platform, Sapian, identifies safe and effective drugs in silico, focusing on small molecule drugs and targeted protein degraders. Sapian demonstrates an ability to find effective modulators of biological targets with over 25% of tested molecules acting on the target of interest, a significant improvement over classical screens. The platform can be applied to various diseases including oncology, neurology, and muscular diseases, and also designs drugs with fewer side effects by predicting pharmacodynamic and pharmacokinetic profiles. Kantify aims to revolutionize human health by finding drugs faster and with fewer resources than traditional methods. Their business model appears to be focused on drug development and potential partnerships, as indicated by their 'Partner with us' section.
Kantify
Kantify is a company leveraging Artificial Intelligence (AI) to accelerate drug discovery and develop breakthrough therapies. Their AI platform, Sapian, identifies safe and effective drugs in silico, focusing on small molecule drugs and targeted protein degraders. Sapian demonstrates an ability to find effective modulators of biological targets with over 25% of tested molecules acting on the target of interest, a significant improvement over classical screens. The platform can be applied to various diseases including oncology, neurology, and muscular diseases, and also designs drugs with fewer side effects by predicting pharmacodynamic and pharmacokinetic profiles. Kantify aims to revolutionize human health by finding drugs faster and with fewer resources than traditional methods. Their business model appears to be focused on drug development and potential partnerships, as indicated by their 'Partner with us' section.